Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study
-
Add time:08/15/2019 Source:sciencedirect.com
Impulse control disorders such as pathological gambling (PG) are a serious and common adverse effect of dopamine (DA) replacement medication in Parkinson's disease (PD). Patients with PG have increased impulsivity and abnormalities in striatal DA, in common with behavioural and substance addictions in the non-PD population. To date, no studies have investigated the role of extrastriatal dopaminergic abnormalities in PD patients with PG. We used the PET radiotracer, [11C] FLB-457, with high-affinity for extrastriatal DA D2/3 receptors. 14 PD patients on DA agonists were imaged while they performed a gambling task involving real monetary reward and a control task. Trait impulsivity was measured with the Barratt Impulsivity Scale (BIS). Seven of the patients had a history of PG that developed subsequent to DA agonist medication. Change in [11C] FLB-457 binding potential (BP) during gambling was reduced in PD with PG patients in the midbrain, where D2/D3 receptors are dominated by autoreceptors. The degree of change in [11C] FLB-457 binding in this region correlated with impulsivity. In the cortex, [11C] FLB-457 BP was significantly greater in the anterior cingulate cortex (ACC) in PD patients with PG during the control task, and binding in this region was also correlated with impulsivity. Our findings provide the first evidence that PD patients with PG have dysfunctional activation of DA autoreceptors in the midbrain and low DA tone in the ACC. Thus, altered striatal and cortical DA homeostasis may incur vulnerability for the development of PG in PD, linked with the impulsive personality trait.
We also recommend Trading Suppliers and Manufacturers of FLB 457 (cas 107188-66-9). Pls Click Website Link as below: cas 107188-66-9 suppliers
Prev:Research reportExtrastriatal D2 and striatal D2 receptors in depressive illness: Pilot PET studies using [11C]FLB 457 (cas 107188-66-9) and [11C]raclopride
Next:Increased dopamine release in the right anterior cingulate cortex during the performance of a sorting task: A [11C]FLB 457 (cas 107188-66-9) PET study) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- [11C]Cyclopropyl-FLB 457 (cas 107188-66-9): A PET radioligand for low densities of dopamine D2 receptors08/21/2019
- A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 (cas 107188-66-9) and [11C]WAY 10063508/20/2019
- Regular ArticleError Analysis for Quantification of [11C]FLB 457 (cas 107188-66-9) Binding to Extrastriatal D2 Dopamine Receptors in the Human Brain08/19/2019
- Regular ArticlePET Mapping of Extrastriatal D2-like Dopamine Receptors in the Human Brain Using an Anatomic Standardization Technique and [11C]FLB 457 (cas 107188-66-9)08/18/2019
- Original articlePreparation of [76Br]FLB 457 (cas 107188-66-9) and [76Br]FLB 463 for examination of striatal and extrastriatal dopamine D-2 receptors with PET08/17/2019
- Increased dopamine release in the right anterior cingulate cortex during the performance of a sorting task: A [11C]FLB 457 (cas 107188-66-9) PET study08/16/2019
- Research reportExtrastriatal D2 and striatal D2 receptors in depressive illness: Pilot PET studies using [11C]FLB 457 (cas 107188-66-9) and [11C]raclopride08/14/2019
- Error analysis for PET measurement of dopamine D2 receptor occupancy by antipsychotics with [11C]raclopride and [11C]FLB 457 (cas 107188-66-9)08/13/2019
- Biodistribution and radiation dosimetry in humans of [11C]FLB 457 (cas 107188-66-9), a positron emission tomography ligand for the extrastriatal dopamine D2 receptor☆08/12/2019


